Real Patient Case Studies Case Study #1: Executive Recovery and Body Recomposition Patient: 47-year-old male tech executive Chief Complaints: Poor recovery from workouts, increasing abdominal fat despite consistent exercise, declining sleep quality, mental fog Baseline Labs: IGF-1: 142 ng/mL (low for age) Testosterone: 387 ng/dL (low-normal) Body fat: 26% (DEXA) Visceral fat area: 187 cm (elevated risk) hs-CRP: 3.2 mg/L (elevated inflammation) Treatment Protocol: Weeks 1-4: Optimize testosterone to 700+ ng/dL using testosterone cypionate, address vitamin D deficiency (was 24 ng/mL) Weeks 5-20: Add sermorelin 300 mcg nightly, 6 days/week Weeks 21-32: Add tesamorelin 2 mg daily to target stubborn visceral fat 32-Week Results: IGF-1: 267 ng/mL (+89%) Body fat: 18.5% (-7.5 percentage points) Lean mass: +6.8 kg gained Visceral fat area: 98 cm (-48% reduction) hs-CRP: 0.8 mg/L (normalized) Sleep: Improved from 5.5 to 7.2 hours average, with 23% increase in deep sleep (Whoop tracking) Patient Report: The combination of testosterone optimization and peptides was transformative
We know for many people that it is an absolute life changer, said Louisiana Health Secretary Bruce Greenstein, who added that the state will apply to participate in Trumps program to lower GLP-1 costs
Generalmente, los medicamentos para la diabetes en la clase de los agonistas del pptido similar al glucagn tipo 1 se reciben mediante una inyeccin que se administra a diario o semanalmente, algunos de estos son: Dulaglutida (Trulicity) Semaglutida (Ozempic, Rybelsus) Liraglutida (Victoza, Saxenda) Estos medicamentos imitan la accin de una hormona llamada pptido similar al glucagn tipo 1
Enfoque en los ingredientes activos
Bloating and GLP-1 Medications: How to Minimize Discomfort If youre just starting out with GLP-1 medications, you might be experiencing some digestive side effects while your system is adjusting to your new routine
